Vicore Pharma to Present at the European Respiratory Society Congress 2026

Rhea-AI Summary

Vicore Pharma (NASDAQ:VCRE, Nasdaq Stockholm:VICO) will present at the European Respiratory Society (ERS) Congress 2026, held September 5–9 in Barcelona and online. The company will share new data on the design and baseline characteristics of patients in its global 52-week Phase 2b ASPIRE trial of buloxibutid in idiopathic pulmonary fibrosis (IPF), and translational findings on angiotensin II type 2 receptor activation in alveolar epithelial type II cells and MMP-13.

An oral presentation on ASPIRE-IPF is scheduled for September 7, 2026 at 11:35 CEST, and a poster on buloxibutid’s AT2 receptor activation and association with fibrosis resolution will be presented September 6, 2026 at 12:30 CEST. According to Vicore Pharma, ASPIRE completed enrollment in April 2026 with over 360 patients at more than 100 sites in 14 countries, enabling topline results in mid-2027. Presentation materials will be posted on the company’s website.

Market Context

The prior investor-forum event carried a -7.54% 24-hour reaction, giving this presentation a negativ...

Analysis

The prior investor-forum event carried a -7.54% 24-hour reaction, giving this presentation a negative historical comparison. The announcement remains focused on trial design, so efficacy risk is unresolved.

Key Figures

Trial phase: Phase 2b Trial duration: 52 weeks High dose: 100 mg twice daily +5 more

8 metrics

Trial phase Phase 2b ASPIRE trial in idiopathic pulmonary fibrosis

Trial duration 52 weeks Global ASPIRE trial

High dose 100 mg twice daily Buloxibutid treatment arm

Low dose 50 mg twice daily Buloxibutid treatment arm

Enrollment More than 360 patients ASPIRE trial enrollment

Trial sites Over 100 sites ASPIRE trial enrollment network

Countries 14 countries ASPIRE trial enrollment network

IPF population Approximately 250,000 people United States and Europe

Historical Context

1 past event · Latest: Jul 07 (Neutral)

Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 07	Investor forum participation	Neutral	-7.5%	Participation in Leerink Therapeutics Forum followed by a negative 24-hour price reaction

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The available comparable investor-forum participation was followed by a negative 24-hour reaction of -7.54%.

Key Terms

idiopathic pulmonary fibrosis, angiotensin ii type 2 receptor agonist, mmp-13, fvc, +2 more

6 terms

idiopathic pulmonary fibrosis medical

"buloxibutid, the company's lead program in idiopathic pulmonary fibrosis (IPF)"

Idiopathic pulmonary fibrosis is a chronic lung disease in which the air‑carrying tissue becomes progressively thickened and scarred for no identifiable reason, making the lungs stiff and less able to move oxygen—similar to a sponge that hardens and loses its pores. It matters to investors because it is life‑limiting with limited effective treatments, so clinical trial outcomes, regulatory approvals, pricing and reimbursement decisions can strongly affect the commercial value of therapies and the financial prospects of companies developing treatments.

angiotensin ii type 2 receptor agonist medical

"buloxibutid, an angiotensin II type 2 receptor agonist, in idiopathic pulmonary fibrosis"

A molecule that binds to and activates the angiotensin II type 2 receptor (AT2R), a specific protein on cell surfaces that triggers biological pathways involved in blood vessel tone, inflammation, tissue repair and organ protection. Think of the receptor as a lock and the agonist as a key that turns it on to produce a cellular response. These drugs matter to investors because they represent a category of therapeutic candidates with potential clinical and commercial impact in cardiovascular, renal and fibrotic conditions.

mmp-13 medical

"its association with MMP-13, a collagenase linked to fibrosis resolution"

mmp-13 (matrix metalloproteinase‑13) is an enzyme that breaks down collagen and other structural proteins in the tissue surrounding cells, helping remodel or degrade the extracellular matrix. It matters to investors because it is a common drug target and biomarker in diseases such as osteoarthritis, certain cancers and fibrotic conditions; drugs or diagnostics that inhibit or measure MMP‑13 can affect the development, regulatory path and commercial prospects of biotech and pharmaceutical products, much like trying to blunt or detect a pair of biochemical scissors.

fvc medical

"change from baseline in forced vital capacity (FVC) at 52 weeks"

Forced vital capacity (FVC) is a lung function measurement that records how much air a person can forcefully exhale after taking the deepest breath possible, similar to timing and measuring a strong, single blow to extinguish a candle. Investors care because FVC is a common clinical trial endpoint for respiratory drugs and devices; meaningful improvements or declines can influence trial success, regulatory approval odds, labeling, and ultimately commercial prospects.

orphan drug regulatory

"has received Orphan Drug and Fast Track designation from the United States"

A drug designated for an orphan disease is a medicine developed to treat a rare condition that affects only a small number of people. Regulators often give these drugs special incentives—such as reduced costs, faster review, and temporary exclusive selling rights—to encourage development, which matters to investors because those incentives can make a small market financially viable and reduce competition, much like a temporary patent on a niche product.

fast track designation regulatory

"received Orphan Drug and Fast Track designation from the United States"

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

STOCKHOLM, SE / ACCESS Newswire / August 24, 2026 / Vicore Pharma Holding AB (NASDAQ Stockholm:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists, today announced that the company will participate in the European Respiratory Society (ERS) Congress 2026, taking place in Barcelona, Spain and online September 5-9, 2026.

Vicore will present new data on the design and baseline characteristics of patients enrolled in the global Phase 2b ASPIRE trial in buloxibutid, the company's lead program in idiopathic pulmonary fibrosis (IPF), along with translational findings on AT2 receptor activation in alveolar epithelial type II cells and its association with MMP-13, a collagenase linked to fibrosis resolution.

Oral presentation: ASPIRE-IPF, a global, double-blind, randomized, placebo-controlled Phase 2b trial of buloxibutid, an angiotensin II type 2 receptor agonist, in idiopathic pulmonary fibrosis: trial design and patient characteristics
Presenter: Toby Maher (Los Angeles, California, United States)
Presented within the session: Moving forward in interstitial lung disease: new data on novel therapies
Date: Monday, September 7, 2026
Presentation Time: 11:35 CEST

Poster: Buloxibutid (C21) activates the angiotensin II type 2 receptor in alveolar epithelial type II cells, increasing MMP-13 associated with fibrosis resolution in idiopathic pulmonary fibrosis
First author: Johan Raud (Stockholm, Sweden)
Presented within the Poster session: Metabolic pathways in pulmonary fibrosis
Date: Sunday, September 6, 2026
Presentation Time: 12:30 CEST

Following the presentations, the materials will be made available on the Publications page of Vicore's website.

For further information, please contact:
Hans Jeppsson, CFO, tel: +46 70 553 14 65, hans.jeppsson@vicorepharma.com

About Vicore Pharma
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.com

About Idiopathic Pulmonary Fibrosis (IPF)
IPF is a progressive and lethal fibrotic lung disease impacting approximately 250,000 people across the United States and Europe. The average life expectancy following diagnosis is 3-5 years, and currently approved therapies only slow the decline of lung function. While there are three anti-fibrotic therapies available today, a large proportion of patients do not initiate treatment, and those who do often discontinue due to limited efficacy and significant tolerability issues. With a growing patient population, there is a clear need for new disease-modifying treatments.

About the Phase 2b ASPIRE Trial
ASPIRE is an ongoing global 52-week Phase 2b, randomized, double-blind, placebo-controlled clinical trial designed to assess the efficacy and safety of buloxibutid in IPF patients who are either not currently on treatment or are receiving standard of care (nintedanib or nerandomilast). Participants are randomized to receive one of two doses of buloxibutid (100 mg or 50 mg taken orally twice daily) or placebo. The primary endpoint is change from baseline in forced vital capacity (FVC) at 52 weeks, the registrational endpoint for IPF. Secondary endpoints include safety, tolerability, and the proportion of patients with disease progression over the trial period. The trial completed enrollment in April 2026, with more than 360 patients enrolled across over 100 sites in 14 countries, including the United States. Recruitment was completed ahead of schedule, positioning the company to report topline results in mid-2027.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements concerning Vicore Pharma, its leadership, its pipeline, and the development of buloxibutid. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks identified in the section entitled "Risk Factors" in Vicore Pharma's filings with the U.S. Securities and Exchange Commission and discussed in Vicore Pharma's Swedish filings, its press releases, and the Registration Statements. Forward-looking statements include, among others, anticipated presentations at the upcoming ERS Congress, the timing of topline results from the Phase 2b ASPIRE clinical trial, and the treatment potential of buloxibutid in IPF. Vicore Pharma cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Vicore Pharma disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Vicore Pharma's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

Attachments
Vicore Pharma to Present at the European Respiratory Society Congress 2026

SOURCE: Vicore Pharma Holding

View the original press release on ACCESS Newswire

FAQ

What will Vicore Pharma (VCRE) present at the European Respiratory Society Congress 2026?

Vicore Pharma will present new Phase 2b ASPIRE trial design and baseline data in IPF, plus translational findings on AT2 receptor activation. According to Vicore Pharma, these include an oral ASPIRE-IPF presentation and a poster on buloxibutid’s effects on MMP-13 and fibrosis resolution.

When and where is Vicore Pharma (VCRE) presenting its ASPIRE-IPF trial data at ERS 2026?

Vicore Pharma’s ASPIRE-IPF oral presentation is scheduled for Monday, September 7, 2026, at 11:35 CEST in Barcelona and online. According to Vicore Pharma, this talk is part of the session “Moving forward in interstitial lung disease: new data on novel therapies.”

What is the Phase 2b ASPIRE trial of buloxibutid in IPF that Vicore Pharma (VCRE) is discussing?

ASPIRE is a global 52-week randomized, double-blind, placebo-controlled Phase 2b trial evaluating buloxibutid in idiopathic pulmonary fibrosis. According to Vicore Pharma, it enrolls treated and untreated IPF patients and assesses efficacy and safety versus placebo, with forced vital capacity change at 52 weeks as the primary endpoint.

How many patients are enrolled in Vicore Pharma’s Phase 2b ASPIRE trial and when are topline results expected?

More than 360 patients are enrolled in the ASPIRE trial across over 100 sites in 14 countries. According to Vicore Pharma, enrollment was completed in April 2026, positioning the company to report topline results in mid-2027 for its buloxibutid IPF program.

What is buloxibutid and why is it important for Vicore Pharma (VCRE) investors?

Buloxibutid is Vicore Pharma’s oral small molecule angiotensin II type 2 receptor agonist being investigated for idiopathic pulmonary fibrosis. According to Vicore Pharma, it has Orphan Drug and Fast Track designations from the U.S. FDA and is the lead asset in the company’s Phase 2b ASPIRE trial.

What is the poster from Vicore Pharma (VCRE) about at ERS 2026 and when is it presented?

Vicore Pharma’s poster describes how buloxibutid activates the AT2 receptor in alveolar epithelial type II cells, increasing MMP-13 associated with fibrosis resolution in IPF. According to Vicore Pharma, the poster will be presented Sunday, September 6, 2026, at 12:30 CEST.